FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2474913089> ?p ?o ?g. }

• W2474913089 endingPage "161" @default.
• W2474913089 startingPage "153" @default.
• W2474913089 abstract "GSK2647544 is a potent and specific inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2), which was in development as a potential treatment for Alzheimer’s disease (AD). In order to refine therapeutic dose predictions and confirm brain penetration, a radiolabelled form of the inhibitor, [18F]GSK2647544, was manufactured for use in a positron emission tomography (PET) biodistribution study. [18F]GSK2647544 was produced using a novel, copper iodide (Cu(I)) mediated, [18F]trifluoromethylation methodology. Healthy male subjects (n = 4, age range 34–42) received an oral dose of unlabelled GSK2647544 (100 mg) and after 2 h an intravenous (iv) injection of [18F]GSK2647544 (average injected activity and mass were 106 ± 47 MBq and 179 ± 55 μg, respectively) followed by dynamic PET scans for 120 min. Defined regions of interest (ROI) throughout the brain were used to obtain regional time-activity curves (TACs) and compartmental modelling analysis used to estimate the primary outcome measure, whole brain volume of distribution (VT). Secondary PK and safety endpoints were also recorded. PET dynamic data were successfully obtained from all four subjects and there were no clinically significant variations of the safety endpoints. Inspection of the TACs indicated a relatively homogenous uptake of [18F]GSK2647544 across all the ROIs examined. The mean whole brain VT was 0.56 (95 % CI, 0.41–0.72). Secondary PK parameters, Cmax (geometric mean) and Tmax (median), were 354 ng/ml and 1.4 h, respectively. Metabolism of GSK2647544 was relatively consistent across subjects, with 20–40 % of the parent compound [18F]GSK2647544 present after 120 min. The study provides evidence that GSK2647544 is able to cross the blood brain barrier in healthy male subjects leading to a measurable brain exposure. The administered doses of GSK2647544 were well tolerated. Exploratory modelling suggested that a twice-daily dose of 102 mg, at steady state, would provide ~80 % trough inhibition of brain Lp-PLA2 activity. Clintrials.gov: NCT01924858." @default.
• W2474913089 created "2016-07-22" @default.
• W2474913089 creator A5000202776 @default.
• W2474913089 creator A5005098704 @default.
• W2474913089 creator A5012375041 @default.
• W2474913089 creator A5015264327 @default.
• W2474913089 creator A5036685224 @default.
• W2474913089 creator A5042140314 @default.
• W2474913089 creator A5042538379 @default.
• W2474913089 creator A5043723583 @default.
• W2474913089 creator A5047102805 @default.
• W2474913089 creator A5050583771 @default.
• W2474913089 creator A5053121423 @default.
• W2474913089 creator A5087503362 @default.
• W2474913089 creator A5087675404 @default.
• W2474913089 date "2016-07-11" @default.
• W2474913089 modified "2023-09-26" @default.
• W2474913089 title "Investigation of the Brain Biodistribution of the Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitor [18F]GSK2647544 in Healthy Male Subjects" @default.
• W2474913089 cites W1736033689 @default.
• W2474913089 cites W1977200885 @default.
• W2474913089 cites W1984327671 @default.
• W2474913089 cites W1986536401 @default.
• W2474913089 cites W1996323095 @default.
• W2474913089 cites W1997764369 @default.
• W2474913089 cites W2003025215 @default.
• W2474913089 cites W2003686994 @default.
• W2474913089 cites W2006106395 @default.
• W2474913089 cites W2007398656 @default.
• W2474913089 cites W2017022537 @default.
• W2474913089 cites W2050591986 @default.
• W2474913089 cites W2058906900 @default.
• W2474913089 cites W2059950637 @default.
• W2474913089 cites W2083681924 @default.
• W2474913089 cites W2094943998 @default.
• W2474913089 cites W2112278807 @default.
• W2474913089 cites W2120095464 @default.
• W2474913089 cites W2129442979 @default.
• W2474913089 cites W2142635246 @default.
• W2474913089 cites W50565577 @default.
• W2474913089 doi "https://doi.org/10.1007/s11307-016-0982-5" @default.
• W2474913089 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5209404" @default.
• W2474913089 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27402093" @default.
• W2474913089 hasPublicationYear "2016" @default.
• W2474913089 type Work @default.
• W2474913089 sameAs 2474913089 @default.
• W2474913089 citedByCount "13" @default.
• W2474913089 countsByYear W24749130892018 @default.
• W2474913089 countsByYear W24749130892019 @default.
• W2474913089 countsByYear W24749130892021 @default.
• W2474913089 countsByYear W24749130892022 @default.
• W2474913089 countsByYear W24749130892023 @default.
• W2474913089 crossrefType "journal-article" @default.
• W2474913089 hasAuthorship W2474913089A5000202776 @default.
• W2474913089 hasAuthorship W2474913089A5005098704 @default.
• W2474913089 hasAuthorship W2474913089A5012375041 @default.
• W2474913089 hasAuthorship W2474913089A5015264327 @default.
• W2474913089 hasAuthorship W2474913089A5036685224 @default.
• W2474913089 hasAuthorship W2474913089A5042140314 @default.
• W2474913089 hasAuthorship W2474913089A5042538379 @default.
• W2474913089 hasAuthorship W2474913089A5043723583 @default.
• W2474913089 hasAuthorship W2474913089A5047102805 @default.
• W2474913089 hasAuthorship W2474913089A5050583771 @default.
• W2474913089 hasAuthorship W2474913089A5053121423 @default.
• W2474913089 hasAuthorship W2474913089A5087503362 @default.
• W2474913089 hasAuthorship W2474913089A5087675404 @default.
• W2474913089 hasBestOaLocation W24749130891 @default.
• W2474913089 hasConcept C112705442 @default.
• W2474913089 hasConcept C126322002 @default.
• W2474913089 hasConcept C139254425 @default.
• W2474913089 hasConcept C181199279 @default.
• W2474913089 hasConcept C185592680 @default.
• W2474913089 hasConcept C202751555 @default.
• W2474913089 hasConcept C22979827 @default.
• W2474913089 hasConcept C2775842073 @default.
• W2474913089 hasConcept C2776551241 @default.
• W2474913089 hasConcept C2777807558 @default.
• W2474913089 hasConcept C2989005 @default.
• W2474913089 hasConcept C55493867 @default.
• W2474913089 hasConcept C71924100 @default.
• W2474913089 hasConcept C98274493 @default.
• W2474913089 hasConceptScore W2474913089C112705442 @default.
• W2474913089 hasConceptScore W2474913089C126322002 @default.
• W2474913089 hasConceptScore W2474913089C139254425 @default.
• W2474913089 hasConceptScore W2474913089C181199279 @default.
• W2474913089 hasConceptScore W2474913089C185592680 @default.
• W2474913089 hasConceptScore W2474913089C202751555 @default.
• W2474913089 hasConceptScore W2474913089C22979827 @default.
• W2474913089 hasConceptScore W2474913089C2775842073 @default.
• W2474913089 hasConceptScore W2474913089C2776551241 @default.
• W2474913089 hasConceptScore W2474913089C2777807558 @default.
• W2474913089 hasConceptScore W2474913089C2989005 @default.
• W2474913089 hasConceptScore W2474913089C55493867 @default.
• W2474913089 hasConceptScore W2474913089C71924100 @default.
• W2474913089 hasConceptScore W2474913089C98274493 @default.
• W2474913089 hasFunder F4320307773 @default.
• W2474913089 hasIssue "1" @default.
• W2474913089 hasLocation W24749130891 @default.
• W2474913089 hasLocation W24749130892 @default.

• next